Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:878132.
doi: 10.1155/2015/878132. Epub 2015 Aug 12.

Efficacy and Safety of Artesunate-Amodiaquine versus Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium falciparum Malaria in Sentinel Sites across Côte d'Ivoire

William Yavo  1 , Abibatou Konaté  2 , Fulgence Kondo Kassi  3 , Vincent Djohan  2 , Etienne Kpongbo Angora  2 , Pulcherie Christiane Kiki-Barro  2 , Henriette Vanga-Bosson  2 , Eby Ignace Hervé Menan  3
Affiliations

Efficacy and Safety of Artesunate-Amodiaquine versus Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium falciparum Malaria in Sentinel Sites across Côte d'Ivoire

William Yavo et al. Malar Res Treat. 2015.

Abstract

Two years after the introduction of free Artesunate-Amodiaquine (ASAQ) and Artemether-Lumefantrine (AL) for the treatment of uncomplicated malaria in public health facilities in Côte d'Ivoire, we carried out this study to compare their efficacy and tolerability in three surveillance sites. It was a multicentre open randomised clinical trial of 3-day ASAQ treatment against AL for the treatment of 2 parallel groups of patients aged 2 years and above. The endpoints were (1) Adequate Clinical and Parasitological Response (ACPR) at day 28 and (2) the clinical and biological tolerability. Of the 300 patients who were enrolled 289, with 143 (49.5%) and 146 (50.5%) in the ASAQ and AL groups, respectively, correctly followed the WHO 2003 protocol we used. The PCR-corrected ACPR was 99.3% for each group. More than 94% of patients no longer showed signs of fever, 48 hours after treatment. Approximately 78% of the people in the ASAQ group had a parasite clearance time of 48 hours or less compared to 81% in the AL group (p = 0.496). Both drugs were found to be well tolerated by the patients. This study demonstrates the effectiveness and tolerability of ASAQ and AL supporting their continuous use for the treatment of uncomplicated P. falciparum malaria infection in Côte d'Ivoire.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial profile.
Figure 2
Figure 2
Parasite clearance in the two groups. ∗ Pearson's Chi-squared test; p value = 0.496.
Figure 3
Figure 3
Fever clearance in the two groups. ∗ Pearson's Chi-squared test; p value = 0.00086.
Figure 4
Figure 4
Changing patterns for gametocyte carriers' number.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. World Malaria Report. Geneva, Switzerland: World Health Organization; 2013.
    1. Ministère de la Santé et de l'Hygiène Publique. PNLP. Directives de prise en charge du paludisme. Abidjan, Côte d'Ivoire: PNLP; 2008.
    1. Brice B. K., William Y., Lacina O., et al. In vitro susceptibility of Plasmodium falciparum isolates from Abidjan, Côte d'Ivoire, to artemisinin, chloroquine, dihydroartemisinin and pyronaridine. Tanzania Journal of Health Research. 2010;12(supplement 1):73–79. - PubMed
    1. World Health Organization. Antimalarial Drug Combination Therapy: Report of a Technical Consultation. Geneva, Switzerland: World Health Organization; 2001.
    1. Ministère de la santé et de l’hygiène publique. Arrêté N°024/CAB/MSHP du 02 janvier 2007 portant institution d’un schéma thérapeutique pour le traitement du paludisme en Côte d’Ivoire. Abidjan: Journal officiel, 2007.

LinkOut - more resources